Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways

• Autores principales: Michelle M. Williams (Autor), Sabrina A. Hafeez (Autor), Jessica L. Christenson (Autor), Kathleen I. O'Neill (Autor), Nia G. Hammond (Autor), Jennifer K. Richer (Autor)
• Formato: Libro
• Publicado: MDPI AG, 2021-11-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Approval of checkpoint inhibitors for treatment of metastatic triple negative breast cancer (mTNBC) has opened the door for the use of immunotherapies against this disease. However, not all patients with mTNBC respond to current immunotherapy approaches such as checkpoint inhibitors. Recent evidence...